How much scrutiny and stress can the fidelis lead withstand?

Circulation

Volumn 123, Issue 4, 2011, Pages 353-354

  Fischer, Avi ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

implantable cardioverter defibrillator; lead failure

Indexed keywords

DEFIBRILLATOR; EDITORIAL; ELECTRIC POTENTIAL; ELECTRODE; PACEMAKER; PATIENT CARE; PHYSICAL ACTIVITY; PRIORITY JOURNAL;

DEFIBRILLATORS, IMPLANTABLE; EQUIPMENT DESIGN; FEMALE; HUMANS; MALE; PROSTHESIS FAILURE; SEX FACTORS; STRESS, MECHANICAL;

EID: 79751526500     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.005215     Document Type: Editorial

References (11)

1. Kleemann T, Becker T, Doenges K, Vater M, Senges J, Schneider S, Saggau W, Weisse U, Seidl K. Annual rate of transvenous defibrillation lead defects in implantable cardioverter-defibrillators over a period of-10 years. (Pubitemid 46763220)
2. Undavia M, Fischer A, Mehta D. Fatal outcome in a pacemakerdependent patient. Pacing Clin Electrophysiol. 2009;32:550-553.
3. Hauser RG, Kallinen LM, Almquist AK, Gornick CC, Katsiyiannis WT. Early failure of a small-diameter high-voltage implantable cardioverterdefibrillator lead. Heart Rhythm. 2007;4:892-896. (Pubitemid 46959208)
4. Parkash R, Crystal E, Bashir J, Simpson C, Birnie D, Sterns L, Exner D, Thibault B, Connors S, Healey JS, Champagne J, Cameron D, Mangat I, Verma A, Wolfe K, Essebag V, Kus T, Ayala-Paredes F, Davies T, Sanatani S, Gow R, Coutu B, Sivakumaran S, Stephenson E, Krahn A. Complications associated with revision of Sprint Fidelis leads: report from the Canadian Heart Rhythm Society Device Advisory Committee. Circulation. 2010;121:2384-2387.
5. Maytin M, Love CJ, Fischer A, Carrillo RG, Garisto JD, Bongiorni MG, Segreti L, John RM, Michaud GF, Albert CM, Epstein LM. Multicenter experience with extraction of the Sprint Fidelis implantable cardioverterdefibrillator lead. J Am Coll Cardiol. 2010;56:646-650.
6. Hauser RG, Maisel WH, Friedman PA, Kallinen LM, Mugglin AS, Kumar K, Hodge DO, Morrison TB, Hayes DL. Longevity of Sprint Fidelis implantable cardioverter-defibrillator leads and risk factors for failure: implications for patient management. Circulation. 2011;123: 358-363.
7. Hauser RG, Maron BJ, Marine JE, Lampert R, Kadish AH, Winters SL, Scher DL, Biria M, Kalia A. Safety and efficacy of transvenous highvoltage implantable cardioverter-defibrillator leads in high-risk hypertrophic cardiomyopathy patients. Heart Rhythm. 2008;5:1517-1522.
8. Morrison TB, Rea RF, Hodge DO, Crusan D, Koestler C, Asirvatham SJ, Bradley D, Shen WK, Munger TM, Hammill SC, Friedman PA. Risk factors for implantable defibrillator lead fracture in a recalled and a nonrecalled lead. J Cardiovasc Electrophysiol. 2010;21:671-677.
9. Farwell D, Green MS, Lemery R, Gollob MH, Birnie DH. Accelerating risk of Fidelis lead fracture. Heart Rhythm. 2008;5:1375-1379.
10. Faulknier BA, Traub DM, Aktas MK, Aguila A, Rosero S, Daubert JP, Hall B, Shah A, Taylor S, McNitt S, Moss AJ, Zareba W, Huang DT. Time-dependent risk of Fidelis lead failure. Am J Cardiol. 2010;105: 95-99.
11. Swerdlow CD, Ellenbogen KA. The changing presentation of implantable cardioverter-defibrillator lead fractures. Heart Rhythm. 2009;6:478-479.